EP1838214A1 - Method and device for identifying, measuring and analyzing abnormal neurological responses - Google Patents
Method and device for identifying, measuring and analyzing abnormal neurological responsesInfo
- Publication number
- EP1838214A1 EP1838214A1 EP05771542A EP05771542A EP1838214A1 EP 1838214 A1 EP1838214 A1 EP 1838214A1 EP 05771542 A EP05771542 A EP 05771542A EP 05771542 A EP05771542 A EP 05771542A EP 1838214 A1 EP1838214 A1 EP 1838214A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- measuring
- accordance
- muscles
- emg
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 11
- 230000000926 neurological effect Effects 0.000 title claims abstract description 8
- 230000004044 response Effects 0.000 title abstract description 19
- 210000003205 muscle Anatomy 0.000 claims abstract description 65
- 238000004364 calculation method Methods 0.000 claims abstract description 18
- 230000036407 pain Effects 0.000 claims abstract description 18
- 208000002193 Pain Diseases 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 21
- 210000003169 central nervous system Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 238000004422 calculation algorithm Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 description 24
- 206010016256 fatigue Diseases 0.000 description 14
- 230000001095 motoneuron effect Effects 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 238000002567 electromyography Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000000663 muscle cell Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 206010044565 Tremor Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010071390 Resting tremor Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/296—Bioelectric electrodes therefor specially adapted for particular uses for electromyography [EMG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
- A61B5/397—Analysis of electromyograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
Definitions
- the present invention relates to a method and device for identifying, measuring and analyzing abnormal neurological responses.
- Abnormal neurological responses are caused among other things by some neuro ⁇ logical diseases, pains, fatigue, problems in power producing ability or in active- ness.
- Electromyography measured from the skin surface describes activation and functioning of muscle cells/motor units during the contraction of a skeletal muscle. It is commonly known that by means of an EMG- signal it is possible to measure activity levels of muscles and from those calculate various quantities describing the functioning of muscles and the body. EMG-signal is usually measured through electrodes placed on the skin overlying muscles.
- the central nervous system recruits in increasing amount muscle cells/motor units in order the muscle power to achieve the func ⁇ tional level to enable the growing mechanical performance.
- muscle power supply e.g. the energy trans ⁇ form of a muscle (e.g. the function of mitochondria) and the distribution of muscle cell types, which depend on the degree of mechanic experience of the muscle, have effect for their part on endurance property of muscle cells.
- Fatigue of a muscle is in accordance with current knowledge also the result of satu ⁇ ration of recruiting processes and response systems on central nervous system level.
- the recruiting of muscle cells changes as the result of the influence of changes in function of the central nervous system and the response systems, in which case the function of motor units in the muscle synchronizes.
- the measured EMG-signal changes to be less complex and its frequency gets lower.
- the EMG- signal of a healthy person is stochastic and even nonstationary / chaotic in some respect.
- abnormal situations e.g. pain, a disease of the central nervous system, Parkinson's disease, lowering of activeness, chronical fatigue, de ⁇ pression
- motor control and its response systems on central nervous system level which changes lead to decreasing of complexity of the EMG- signal.
- diseases on central nervous system level there are typically changes in the functions of neurotransmitters of the brain (e.g. dopamine in Parkinson's disease and serotonin in depression) which partly change the motor firing system and also affect the functions of response systems disadvantageously.
- EMG-signal is usually measured in two different ways depending on what kind of measuring accuracy or analysis of results are wanted or, on the other hand, what kind is the technical operating capacity of measuring equipment.
- the most versatile measuring and analyzing options are achieved by measuring EMG bi-polar as so- called RAW EMG-signal.
- RAW EMG-signal By utilizing sufficiently high sampling frequency, for ex ⁇ ample 1000 - 10000 Hz it is possible to make analysis from a signal, precise enough for scientific research by means of FFT spectrum calculation.
- Equipment, measuring RAW signal has to possess great capacity of processing and great mem- ory capacity. Another typical way of measuring is so-called averaging i.e.
- AVERAGE-EMG method in which method the EMG-signal received from a mus ⁇ cle is first rectified and after that averaged by sliding 0,1 - 1 seconds window over the data area. Typically, loading of muscles is estimated, loading comparisons are made, activating rates and times of muscles are examined and so on by analyzing the AVERAGE-EMG-signal. Measuring of AVERAGE EMG-signal may in princi ⁇ ple be made with a rather simple equipment.
- Each EMG-signal forms a so-called profile, in which active and passive states of the measured muscle may be seen as changes in amplitude of the signal.
- the frequency spectrum of the signal contains information on the function of the mus- cle. Quantities describing the function of muscles among others are: - muscle load and changes in it
- EMG-signals are transmitted typically either to be presented in real-time on a display device or signals are stored in file format for later examination and analyses.
- the received EMG-surface sig ⁇ nal is unstationar, in which case properties and character of signal variation is not possible to be described sufficiently in traditional manners.
- Linear methods such as FFT-analysis may be applied limited for analysing of an EMG-signal while a linear analysis of an unstationar and stochastic signal averages the result and therefore a part of the real information from the signal is lost.
- Symptoms which may not be perceived by traditional methods from EMG, are e.g. indication of pain response and response of changes caused by a signal of a neurological disease.
- nonlinear calculation methods For analyzing of biosignals also nonlinear calculation methods may be used, addi ⁇ tional information from which is not available using traditional methods.
- Nonlinear methods are more applicabable for analysis of stochastic EMG-signal. These kinds of algorithms are e.g. entropy, determinism, complexity-algorithms as well as en- tropic and fractal analyses.
- entropy e.g. entropy, determinism, complexity-algorithms as well as en- tropic and fractal analyses.
- Several nonlinear calculation methods are commonly known. In literature e.g. RQA (recurrence quantification analysis) and Lempel-Ziv complexity have been described. They are proved to be more applicabable than lin ⁇ ear algorithms for analyzing biosignals and therefore their use applied for diagnostic use and monitoring treatment of diseases is essentially better manner.
- Lempel-Ziv-complexity analysis and applying of it in measurements of biosignals is more closely described.
- Lempel-Ziv complexity C(n) searches peri- odicities and regularities in an EMG-signal. "Randomization" of a finite symbol line is therefore estimated by the algorithm.
- a simple line 0000... has the complexity of 2, as 0 and the end part of zero have to be added to it by copying.
- the complexity of line 010101... is 3.
- the complex- ity of a symbol line is defined by a complexity counter c(n), which is received by calculating the number of different occurence forms (words) in given symbol line.
- the number of these occurence forms reveals the complexity or regularity of a sig ⁇ nal.
- Usually received complexity values are normalized to 0-1 or 0-100%.
- RQA Recurrence Quantification Analysis
- Eckmann was the first to publish RQA in 1987 and Webber introduced it in physio ⁇ logical studies in 1994.
- RQA method is not dependent e.g. on the quantity of data or stationarity or statistical distribution of data content, RQA is well applica ⁇ bable in physiological systems, to which sudden changes, variations of levels, noise and so on originating in living organisms are often related. For example, in measur ⁇ ing fatigue the RQA method detects the starting moment faster and more sensitively than the FFT method.
- these analyses have not been used in disease grad ⁇ ing in diagnostic sense.
- the objective of the invention is to provide a method and a device for identifying, measuring and analyzing abnormal neurological responses, with the use of which it is possible to identify easier, more objective and better than with present diagnostic methods phenomena of the central nervous system and the neuromuscular system and symptoms connected with abnormalities.
- the objective of the inven ⁇ tion is to provide a method, witch enables an early diagnozing of neurological dis- eases such as Parkinson's disease and utilizing in dosing medicine.
- neurological diseases, pains, fatigue, power producing ability and/or activeness and/or symptoms related to those are es- timated by measuring signals produced by muscles and by analyzing signals with nonlinear calculation methods.
- Signals produced by muscles are in this context re ⁇ ferred to as signals received by measuring in various ways from muscles and from their functioning.
- nonlinear calculation methods are not described very precise, and the method is not limited to any particular nonlinear calculation method but in the method, one or some nonlin ⁇ ear calculation methods may be used.
- electrical signals of muscles are measured with a measuring device.
- measuring may be made non- invasive on the skin by means of different kinds of measuring sensors.
- the measur ⁇ ing device may be designed to be small by size, easy to handle, wearable and the processing of results may be realized by means of a computer or an embedded measuring system.
- Advantageously electrical signals of active muscles are measured.
- pa- rameters to be calculated from measuring signals may be defined fast and reliably.
- other signals produced by muscles than electrical signals may be measured with a measuring device on the skin by means of suitable measuring sensors.
- acceleration, pressure and tem ⁇ perature are these kinds of signals.
- tremor or functional disorders cause abnormal shapes of acceleration and pressure signals, which shapes may be identified in signal analysis phase.
- time-related stored image se ⁇ ries or bit map describing the recruitment of different parts of muscles produced by means of magnetic resonance imaging (MRI) or ultrasound imaging may represent this kind of measuring manner.
- sensors are not placed on the skin.
- the results received by the method are compared with the reference results stored in a database. In this case, differences between normal and abnormal result, changes and the stage of pathol ⁇ ogy may be defined.
- the results received by the method are transmitted to a user by means of a feedback device.
- the user may be e.g. a relative, a person doing or monitoring the study in a hospital, in a nursing home, at home with the person to be examined or in some other place.
- a dosing of medicine used for treating e.g. Parkinson's disease or some other disease or for some other reason may be optimized in accordance with received results.
- the results received by the method are transmitted to the person examined by means of a personal feedback de ⁇ vice.
- the person him/herself may carry out the test or similar, and get feedback about changes in his/her activeness, development of motoric skills or need for dosing of medicine at home, and while needed get in touch with the person treat ⁇ ing him/her.
- Nonlinear analysis is more applicabable than linear methods for analysis of biosig- nals due to stochastic and non-stationary character of signals.
- analysis more information e.g. about pain reflection and disorders of the motoric and premo- toric functioning model as well as from changes on cerebellum and corpus callosum level may be received.
- weakening of neurotransmitters such as dopa ⁇ mine and serotonin levels affect the complexity of an EMG-signal measured on a muscle and so-called fatigue changes are stronger than on a normal group.
- EEG-signal Functioning of the central nervous system is commonly examined with measuring of so-called EEG-signal, which is carried out through electrodes placed on the scalp.
- EEG measures electrical functioning in the brain. For controlling the body and especially muscles also impulses going through the central and the peripheral nervous system are needed.
- EMG describes the control of the central nervous sys ⁇ tem and the motoric cortex more precise than EEG, while an EEG-signal is con- ducted through the scalp while measuring and EEG contains also responses related to control of vital functions and sense perception.
- the nonlinear estimation method application of an EMG-signal enables e.g. follow ⁇ ing applications:
- results received by the method are compared to a database with reference results stored in it from patients suffering from neurological diseases and, on the other hand, from healthy test persons, it can be seen if the EMG-signal of the person examined has characteristics referring to a disease or deviation of calculation pa- rameters from normal reference values.
- Measurements made by the method and results from those may, while needed to be transmitted to the person who made the study, i.e. the user or to the person who was examined or to relatives by means of various display devices or corresponding feedback devices or to the person who was examined by means of a personal port- able feedback device for possible further actions.
- the method is applied by means of measuring system e.g. for diagnozing of pain and Parkinson's disease, for follow-up of treatment of Parkinson's disease, for ob ⁇ jective measuring of muscle fatigue and in general for follow-up of changes in ac ⁇ tiveness of the central nervous system, in which method from the EMG-signals re- ceived from muscles by means of nonlinear calculation parameters connected with earlier mentioned diseases and symptoms are measured and compared if necessary to reference values gathered in database or to own earlier values concluding from changes or deviations proceeding of a disease, pain status or mentioned application action.
- measuring system e.g. for diagnozing of pain and Parkinson's disease, for follow-up of treatment of Parkinson's disease, for ob ⁇ jective measuring of muscle fatigue and in general for follow-up of changes in ac ⁇ tiveness of the central nervous system, in which method from the EMG-signals re- ceived from muscles by means of nonlinear calculation parameters connected with earlier mentioned diseases and symptoms are measured and
- the method is utilized in diagnosing and treating of Parkinson's disease.
- Patients with Parkinson's disease suffer from changes in motoric control and its response system on the central nervous system level, which changes are caused by changes of dopamine level. These changes may be seen as decreasing of complexity of the EMG-signal, which may be detected by a nonlinear analysis such as e.g. RQA. Based on this the follow-up of Parkinson's disease patients or risk groups may be realized before outbreak of the disease.
- EMG measured on the skin measures responses of motor units of a muscle, but util ⁇ izing nonlinear methods it is possible to analyze primitive mechanisms controlling muscle functioning of the central nervous system level.
- neurological diseases es ⁇ pecially in Parkinson's disease
- these primitive controlling mechanisms are dam ⁇ aged and insufficient by function.
- Parkinson's disease is the most important disease of so-called extrapyramidal system of the brain, the cause of which is unknown.
- 60-80 % of the dopaminergic nigrostriatal pathways of the so-called substantia nigra located in the midbrain has been damaged or they are dysfunc ⁇ tional.
- Parkinson's disease The four main symptoms of Parkinson's disease are resting tremor, rigidity (stiffness), hypokinesia (slowness of movements) and slowening of the correction reflex of balance.
- the most typical symptom is the resting tremor.
- the diagnosis of Parkinson's disease is clinical, which is made on grounds of symptoms and the clinical detections of a physician. There are no objective methods as routine in clini ⁇ cal use. Before Parkinson's disease has been clinically ascertained, the disease proc- ess itself has already proceeded far. By means of newer EMG analysis methods, it is possible to trace the disease already in the early phase of the disease. This would es ⁇ sentially help to make the diagnosis and to start the treatment earlier.
- Figure 1 illustrates an example of an EMG-signal during contraction
- Figure 2a illustrates an EMG-signal of a healthy person
- Figure 2b illustrates an EMG-signal of a Parkinson patient.
- EMG-signal is a sum signal of individual action potentials caused by motor units in a muscle. Normal motoric control of a muscle causes always slight fading in an EMG-signal even visible in the figure as well as separate and oc- casional spikes. Proportion of various deviations on a healthy person is quite small and no regularities may be found.
- FIG 2a and 2b there are EMG measurements of three seconds duration on a healthy control person (figure 2a) and on a Parkinson patient (2b) presented.
- the measurements have been made during an isometric muscle contraction when the load of muscles remains as constant as possible on the average. Differences in re ⁇ cruiting of motor units on the healthy test person and on the Parkinson disease pa ⁇ tient are visible with the eye.
- the signal of the healthy person some individual spikes higher than the variation of the base level may be seen.
- the signal of the Parkinson patient clearly more signal spikes stronger than the base level may be seen and they repeat more regularly and more organized than on the healthy test person. Increasing of strong spikes is caused by interruptions in motoric control.
- the motor units of the muscle function more synchronized among each other, which means growing of the signal level in the EMG-signal.
- the excessive synchronization of motor units means tremor of muscles and absence of fine motoric control necessary for even motion.
- the diagnosis method of Parkinson's disease is based on measuring made on a test person with an EMG-equipment and comparing of measuring results to comparison data in a database.
- an EMG-measurement is carried out on the muscles of the arm as the motoric control of arms is the most developed form of neuromuscular function.
- EMG-signal samples are taken with various standard motion course and power tests, in which case comparison of results with the database is possible.
- the motion courses to be tested are e.g. removing of an object of certain size and weight from one place to another along defined course. Along the course, the arm and the wrist must simultaneously e.g. clasp the object, move in horizontal and vertical di ⁇ rections as well as twist from one extreme position to another.
- the spon ⁇ taneous EMG-responses of the muscle may also be analyzed and separate the healthy and the Parkinson patients on grounds of the measuring data by a normal every day muscle activation analysis.
- the comparison database contains sample data both from the healthy and from the patients in various phases of Parkinson's disease.
- the EMG-sample from a test person may give suggestions not only about the first symptoms of the disease but also about the proceeding degree of the disease.
- the results are normal ⁇ ized on grounds of data base comparison such that the proceeding degree may be categorized with a suitable scale.
- the method may also be applied in dosing of medical treatment of Parkinson's dis ⁇ ease.
- the patient has an automatic dosing apparatus adjusted, which e.g. infuses medicine to the blood circulation or to the small intestine of the patient by means of estimation of the dopamine level based on EMG-measuring.
- EMG-measuring is made, for example, by means of a measuring wristband, which is easy to use and continuously functioning.
- a measuring wristband or other sensor is placed, for ex ⁇ ample, on the hand, feet and so on.
- Response from the measuring signal is analyzed at regular time intervals, for example every 5 min.
- the analysis of which has been carried out by means of some nonlinear algorithms men- tioned has visible signs of falling of the dopamine level, the information is trans ⁇ mitted to the device the patient is carrying.
- the device may be a dosing pump or some other dozer of medicine, which has e.g. an alarm system for starting the dos ⁇ ing or for a dose of medicine to be taken internally.
- sy ⁇ ringing may start automatically through an invasive canule. It is also characteristic to Parkinson's disease that the symptoms appear first on one limb, in which case by comparing signals both on the left and the right limb the ending of the influence of medicine may be anticipated in good time.
- Overdosing of medicine may also cause adaptation of a patient to dopamine as the result of which the influence of medicine dose weakens. At the worst adaptation may facilitate the progression of the disease or cause premature death.
- a possible medicine overdosing may be avoided.
- pain response experienced by pa ⁇ tients suffering from back pain in comparison with feelings of patients with similar by performance ability of muscles but with no pain.
- Condition of back muscles of patients with back problems has weakened and a part of patients suffers from pain also while loading muscles.
- Patients with back pain may be separated from healthy patients who have been through treatment/training by means of FFT method based on linear analysis, but the method does not separate individually pain patients. Identification of pain patients is successful while using the nonlinear RQA method and the method makes it possible to make a measurement from a measuring signal before rehabilitating exercise part and after it, whereas earlier the measurement had to be carried out with a linear method during the whole performance.
- FFT calculation gives suggestive results also during dy ⁇ namic motion but muscle contractions varying continuously and interferences due to motion change the frequency content of the EMG-signal such that the results from FFT calculations are not as precise and reliable as in static measurement.
- FFT calculation made of dynamic motion may be specified by making use of motion sensors attached to a person during the test, by means of which sensors the interfer ⁇ ences created in signals may be eliminated or limit the areas included in FFT calcu ⁇ lation to advantageous in terms of calculation. In this case fatigue may be measured reliably e.g. during work or sports performance with a measuring/displaying device to be carried with a person.
- An advantageous application of the invention measures development of motoric skills of a person.
- the method is utilized e.g. in rehabilitation after a person has been disabled, in training of professions requiring great accuracy or e.g. in sports training.
- EMG-signal is measured from one or several muscles during a perform- ance. During the measurement a specific performance and its training part are aimed to be specified e.g. a golf swing or a tennis serve.
- the measuring sensors are placed on the skin overlying muscles participating in the performance at the middle of the muscle.
- the measuring is carried out through disposable sensors or through sensors integrated in clothing.
- the information of measuring is stored in a measuring device on the wrist, on the waist or in the pocket, which measures the EMG-signal with recognized methods.
- the measuring signal is calculated by means of various calcu ⁇ lation algorithms, by calculating e.g. complexity values during the performance.
- the performance is tried to be separated into various phases and the result of the performance is fed also into the memory of the device.
- Complexity values from the entire performance are calculated and stored into the memory.
- the change is compared to the received performance results. Later on, the values may be utilized while restoring and further developing motoric skills.
- the results may be compared to the values of the data- base and in this way estimate the development of motoric learning and skill objec ⁇ tively.
- the method is utilized for measur ⁇ ing the activeness level of a person which is necessary for follow-up of changes in activeness state of the central nervous system due to various reasons e.g. in connec ⁇ tion with diseases such as dementia, Alzheimer disease, depression, chronic/acute fatigue and so on. Control of the state of fatigueness is useful also in some working positions requiring continuous concentrating such as surgery, flying/air control and so on.
- the median value of a person is defined for complexity, which is compared to reference data.
- the person to be measured carries a measuring device, which measures at regular time intervals e.g. EMG-signal from the muscles of the arms, from which signal some of the parameters complexity, entropy or determin ⁇ ism is calculated. From the value, e.g. the mean value of a day or a week is calcu ⁇ lated.
- the change with respect to the mean value on a long time period describes the change in activeness, variation in serotonin level, motoric learning and so on.
- the device in accordance with the invention comprises sensors to be placed in the body or on the body surface for measuring signals produced by muscles, a device for analysis of the signals by nonlinear calculation methods and a feedback device for giving feedback.
- the device comprises advantageously sensors especially for measuring electrical signals produced by muscles.
- the sensors in themselves are conventional sensors for this purpose.
- the device for analysis of signals processes and analyzes signals and it has the necessary programmes for processing and ana ⁇ lyzing signals with nonlinear calculation methods as earlier presented.
- the device comprises one or several recognized feedback devices, with which the user, the person examined or possibly some other person may receive information about the study and its results in real-time or later. Naturally, the information is also stored for later use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Disabilities (AREA)
- Physiology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
The objective of the invention is a method and a device for identifying, measuring and analyzing abnormal neurological responses. In the method in accordance with the invention neurological diseases, pain, fatigue, power producing ability and/or activeness and/or symptoms connected with those are estimated by measuring signals produced by muscles and by analyzing signals with nonlinear calculation methods. The device in accordance with the invention comprises sensors to be placed in the body or on the body surface for measuring signals produced by muscles, a signal analyzing device for analyzing signals with nonlinear calculation methods and a feedback device for giving feedback.
Description
METHOD AND DEVICE FOR IDENTIFYING, MEASURING AND ANALYZING ABNORMAL NEUROLOGICAL RESPONSES
The present invention relates to a method and device for identifying, measuring and analyzing abnormal neurological responses.
Abnormal neurological responses are caused among other things by some neuro¬ logical diseases, pains, fatigue, problems in power producing ability or in active- ness.
Electric signal of muscles i.e. Electromyography (EMG) measured from the skin surface describes activation and functioning of muscle cells/motor units during the contraction of a skeletal muscle. It is commonly known that by means of an EMG- signal it is possible to measure activity levels of muscles and from those calculate various quantities describing the functioning of muscles and the body. EMG-signal is usually measured through electrodes placed on the skin overlying muscles.
As muscle power increases, the central nervous system recruits in increasing amount muscle cells/motor units in order the muscle power to achieve the func¬ tional level to enable the growing mechanical performance. The accuracy of a me¬ chanical performance and the power supply of a muscle function under a complex response system, in which besides the central nervous system also the golgi tendon organs and muscle bundles with their response systems take part.
Experience of muscles and the size of muscle cells, as well as activeness of the cen¬ tral nervous system have influence on the muscle power supply. The energy trans¬ form of a muscle (e.g. the function of mitochondria) and the distribution of muscle cell types, which depend on the degree of mechanic experience of the muscle, have effect for their part on endurance property of muscle cells.
As a performance lasts longer and the skeletal muscle gets tired, its function changes in accordance with the energy transform and the muscle cell type / distribu¬ tion (fast-twitch/slow-twitch). When tired the conduction velocity of action poten¬ tial gets slower on the membrane of a muscle cell along with saturation of K+ and Na+ ion change and rerecruiting getting slower. In a powerful performance, leading to fatigue of the skeletal muscle the oxygen intake to energy production weakens and the cell acidifies as the result of accumulation of H+ ion concentration inside the cell. As the result the velocity of action potential wave on the muscle membrane gets slower being longer in time (= frequency gets lower).
Fatigue of a muscle is in accordance with current knowledge also the result of satu¬ ration of recruiting processes and response systems on central nervous system level. On central nervous system level as a muscle gets tired, the recruiting of muscle cells changes as the result of the influence of changes in function of the central nervous system and the response systems, in which case the function of motor units in the muscle synchronizes. As the result of this, the measured EMG-signal changes to be less complex and its frequency gets lower.
Typically, the EMG- signal of a healthy person is stochastic and even nonstationary / chaotic in some respect. In abnormal situations (e.g. pain, a disease of the central nervous system, Parkinson's disease, lowering of activeness, chronical fatigue, de¬ pression) there occurs changes of motor control and its response systems on central nervous system level, which changes lead to decreasing of complexity of the EMG- signal. In diseases on central nervous system level, there are typically changes in the functions of neurotransmitters of the brain (e.g. dopamine in Parkinson's disease and serotonin in depression) which partly change the motor firing system and also affect the functions of response systems disadvantageously.
EMG-signal is usually measured in two different ways depending on what kind of measuring accuracy or analysis of results are wanted or, on the other hand, what kind is the technical operating capacity of measuring equipment. The most versatile measuring and analyzing options are achieved by measuring EMG bi-polar as so- called RAW EMG-signal. By utilizing sufficiently high sampling frequency, for ex¬ ample 1000 - 10000 Hz it is possible to make analysis from a signal, precise enough for scientific research by means of FFT spectrum calculation. Equipment, measuring RAW signal has to possess great capacity of processing and great mem- ory capacity. Another typical way of measuring is so-called averaging i.e. AVERAGE-EMG method, in which method the EMG-signal received from a mus¬ cle is first rectified and after that averaged by sliding 0,1 - 1 seconds window over the data area. Typically, loading of muscles is estimated, loading comparisons are made, activating rates and times of muscles are examined and so on by analyzing the AVERAGE-EMG-signal. Measuring of AVERAGE EMG-signal may in princi¬ ple be made with a rather simple equipment.
Each EMG-signal forms a so-called profile, in which active and passive states of the measured muscle may be seen as changes in amplitude of the signal. In addition, the frequency spectrum of the signal contains information on the function of the mus- cle. Quantities describing the function of muscles among others are:
- muscle load and changes in it
- distribution of load on different muscles of the body
- the side-difference between two symmetrical muscles, when loading simultane¬ ously with the same load
- activation order, activation times, reaction times and so on of muscles
- comparison of activation profiles of muscles in various states of a performance and on different test persons
- fatigue of muscles
In addition, from the shape, amplitude, frequency spectrum and changes in those of an EMG-signal it is possible to calculate plenty of other quantities to be monitored and controlled. The measured EMG-signals are transmitted typically either to be presented in real-time on a display device or signals are stored in file format for later examination and analyses.
It is commonly known that the performance level and the degree of fatigueness may be estimated by measuring and analyzing an EMG-signal produced by a muscle. In traditional EMG-analysis, data is studied using linear time-frequency level methods. One method of this kind has been described in US Patent 5,361,775 by Mega Elek- troniikka Oy, among other things, in which by a FFT- i.e. spectrum analysis made from an EMG-signal several quantities correlating with fatigue of a muscle are able to be received. Fatigue of a muscle may be seen in power spectrum of an EMG- signal among other things as lowering of mean-frequency and, on the other hand, as rising of averaged EMG-activity level.
In practical situations, e.g. in a dynamic contraction, the received EMG-surface sig¬ nal is unstationar, in which case properties and character of signal variation is not possible to be described sufficiently in traditional manners. Linear methods such as FFT-analysis may be applied limited for analysing of an EMG-signal while a linear analysis of an unstationar and stochastic signal averages the result and therefore a part of the real information from the signal is lost. Symptoms, which may not be perceived by traditional methods from EMG, are e.g. indication of pain response and response of changes caused by a signal of a neurological disease.
For analyzing of biosignals also nonlinear calculation methods may be used, addi¬ tional information from which is not available using traditional methods. Nonlinear
methods are more applicabable for analysis of stochastic EMG-signal. These kinds of algorithms are e.g. entropy, determinism, complexity-algorithms as well as en- tropic and fractal analyses. Several nonlinear calculation methods are commonly known. In literature e.g. RQA (recurrence quantification analysis) and Lempel-Ziv complexity have been described. They are proved to be more applicabable than lin¬ ear algorithms for analyzing biosignals and therefore their use applied for diagnostic use and monitoring treatment of diseases is essentially better manner.
Next the Lempel-Ziv-complexity analysis and applying of it in measurements of biosignals is more closely described. Lempel-Ziv complexity C(n) searches peri- odicities and regularities in an EMG-signal. "Randomization" of a finite symbol line is therefore estimated by the algorithm.
A simple line 0000... has the complexity of 2, as 0 and the end part of zero have to be added to it by copying. Correspondingly the complexity of line 010101... is 3. In practice a digitized biosignal time series is processed into a symbol line by changing each sample of a time series e.g. to value 0 or 1 depending on whether the sample is bigger or smaller than the set threshold value, which may be, depending on calcula¬ tion algorithm e.g. a mean value level. From a binary symbol line such produced e.g. 001111000011100001111001100011110 as the result of the complexity analy¬ sis we get 0.01.1110.0001.1100001111.00110.0011110 i.e. c(n) = 7. The complex- ity of a symbol line is defined by a complexity counter c(n), which is received by calculating the number of different occurence forms (words) in given symbol line. The number of these occurence forms reveals the complexity or regularity of a sig¬ nal. Usually received complexity values are normalized to 0-1 or 0-100%.
Another frequently used method is so-called RQA i.e. Recurrence Quantification Analysis, which has been developed especially for studying nonlinear systems. Eckmann was the first to publish RQA in 1987 and Webber introduced it in physio¬ logical studies in 1994. As RQA method is not dependent e.g. on the quantity of data or stationarity or statistical distribution of data content, RQA is well applica¬ bable in physiological systems, to which sudden changes, variations of levels, noise and so on originating in living organisms are often related. For example, in measur¬ ing fatigue the RQA method detects the starting moment faster and more sensitively than the FFT method. However, these analyses have not been used in disease grad¬ ing in diagnostic sense.
The objective of the invention is to provide a method and a device for identifying, measuring and analyzing abnormal neurological responses, with the use of which it
is possible to identify easier, more objective and better than with present diagnostic methods phenomena of the central nervous system and the neuromuscular system and symptoms connected with abnormalities. In addition, the objective of the inven¬ tion is to provide a method, witch enables an early diagnozing of neurological dis- eases such as Parkinson's disease and utilizing in dosing medicine.
The objective of the invention is accomplished by a method and device, the charac¬ teristics of which are presented in the claims.
In the method in accordance with the invention neurological diseases, pains, fatigue, power producing ability and/or activeness and/or symptoms related to those are es- timated by measuring signals produced by muscles and by analyzing signals with nonlinear calculation methods. Signals produced by muscles are in this context re¬ ferred to as signals received by measuring in various ways from muscles and from their functioning. As earlier presented, there are several recognized nonlinear calcu¬ lation methods in use, some of which are described earlier. In this paper, nonlinear calculation methods are not described very precise, and the method is not limited to any particular nonlinear calculation method but in the method, one or some nonlin¬ ear calculation methods may be used.
In an advantageous application of the invention, electrical signals of muscles are measured with a measuring device. In this case, measuring may be made non- invasive on the skin by means of different kinds of measuring sensors. The measur¬ ing device may be designed to be small by size, easy to handle, wearable and the processing of results may be realized by means of a computer or an embedded measuring system.
Advantageously electrical signals of active muscles are measured. In this case, pa- rameters to be calculated from measuring signals may be defined fast and reliably. In an advantageous application of the invention, other signals produced by muscles than electrical signals may be measured with a measuring device on the skin by means of suitable measuring sensors. For example, acceleration, pressure and tem¬ perature are these kinds of signals. In neuromuscular diseases, tremor or functional disorders cause abnormal shapes of acceleration and pressure signals, which shapes may be identified in signal analysis phase. In addition, time-related stored image se¬ ries or bit map describing the recruitment of different parts of muscles produced by means of magnetic resonance imaging (MRI) or ultrasound imaging may represent this kind of measuring manner. In these cases, sensors are not placed on the skin.
In the next additional application of the invention, the results received by the method are compared with the reference results stored in a database. In this case, differences between normal and abnormal result, changes and the stage of pathol¬ ogy may be defined.
In the next additional application of the invention, the results received by the method are transmitted to a user by means of a feedback device. The user may be e.g. a relative, a person doing or monitoring the study in a hospital, in a nursing home, at home with the person to be examined or in some other place. In this case, a dosing of medicine used for treating e.g. Parkinson's disease or some other disease or for some other reason may be optimized in accordance with received results.
In the next additional application of the invention, the results received by the method are transmitted to the person examined by means of a personal feedback de¬ vice. In this case the person him/herself may carry out the test or similar, and get feedback about changes in his/her activeness, development of motoric skills or need for dosing of medicine at home, and while needed get in touch with the person treat¬ ing him/her.
Nonlinear analysis is more applicabable than linear methods for analysis of biosig- nals due to stochastic and non-stationary character of signals. By means of analysis more information e.g. about pain reflection and disorders of the motoric and premo- toric functioning model as well as from changes on cerebellum and corpus callosum level may be received. In this case, weakening of neurotransmitters such as dopa¬ mine and serotonin levels affect the complexity of an EMG-signal measured on a muscle and so-called fatigue changes are stronger than on a normal group.
Functioning of the central nervous system is commonly examined with measuring of so-called EEG-signal, which is carried out through electrodes placed on the scalp. EEG measures electrical functioning in the brain. For controlling the body and especially muscles also impulses going through the central and the peripheral nervous system are needed. EMG describes the control of the central nervous sys¬ tem and the motoric cortex more precise than EEG, while an EEG-signal is con- ducted through the scalp while measuring and EEG contains also responses related to control of vital functions and sense perception.
The nonlinear estimation method application of an EMG-signal enables e.g. follow¬ ing applications:
a) Objective estimation of pain
b) Estimation of decreasing of dopamine level of the brain typical of Parkinson's disease, which enables screening of persons in a risk group of Parkinson's disease (identifying of prestages), diagnosing of the disease and the follow-up of progres¬ sion of the disease
c) By means of the method it is possible to time and dose the medical treatment of a patient of Parkinson's disease
d) Objective measuring of muscle fatigue
e) Follow-up of changes in activeness of the central nervous system due to various reasons (e.g. dementia, the Alzheimer disease, depression, chronical/acute fatigue)
f) Follow-up of development of motoric skills of the body and parts of it
When the results received by the method are compared to a database with reference results stored in it from patients suffering from neurological diseases and, on the other hand, from healthy test persons, it can be seen if the EMG-signal of the person examined has characteristics referring to a disease or deviation of calculation pa- rameters from normal reference values.
Measurements made by the method and results from those may, while needed to be transmitted to the person who made the study, i.e. the user or to the person who was examined or to relatives by means of various display devices or corresponding feedback devices or to the person who was examined by means of a personal port- able feedback device for possible further actions.
The method is applied by means of measuring system e.g. for diagnozing of pain and Parkinson's disease, for follow-up of treatment of Parkinson's disease, for ob¬ jective measuring of muscle fatigue and in general for follow-up of changes in ac¬ tiveness of the central nervous system, in which method from the EMG-signals re- ceived from muscles by means of nonlinear calculation parameters connected with earlier mentioned diseases and symptoms are measured and compared if necessary to reference values gathered in database or to own earlier values concluding from changes or deviations proceeding of a disease, pain status or mentioned application action.
In an advantageous application of the invention, the method is utilized in diagnosing and treating of Parkinson's disease. Patients with Parkinson's disease suffer from changes in motoric control and its response system on the central nervous system
level, which changes are caused by changes of dopamine level. These changes may be seen as decreasing of complexity of the EMG-signal, which may be detected by a nonlinear analysis such as e.g. RQA. Based on this the follow-up of Parkinson's disease patients or risk groups may be realized before outbreak of the disease.
EMG measured on the skin measures responses of motor units of a muscle, but util¬ izing nonlinear methods it is possible to analyze primitive mechanisms controlling muscle functioning of the central nervous system level. In neurological diseases, es¬ pecially in Parkinson's disease, these primitive controlling mechanisms are dam¬ aged and insufficient by function. Parkinson's disease is the most important disease of so-called extrapyramidal system of the brain, the cause of which is unknown. In clinical diagnosis as the consequence of the disease has been stated among other things, that 60-80 % of the dopaminergic nigrostriatal pathways of the so-called substantia nigra located in the midbrain has been damaged or they are dysfunc¬ tional. The four main symptoms of Parkinson's disease are resting tremor, rigidity (stiffness), hypokinesia (slowness of movements) and slowening of the correction reflex of balance. The most typical symptom is the resting tremor. The diagnosis of Parkinson's disease is clinical, which is made on grounds of symptoms and the clinical detections of a physician. There are no objective methods as routine in clini¬ cal use. Before Parkinson's disease has been clinically ascertained, the disease proc- ess itself has already proceeded far. By means of newer EMG analysis methods, it is possible to trace the disease already in the early phase of the disease. This would es¬ sentially help to make the diagnosis and to start the treatment earlier.
Next, the invention will be explained in more detail with reference to the accompa¬ nying figures, in which,
Figure 1 illustrates an example of an EMG-signal during contraction,
Figure 2a illustrates an EMG-signal of a healthy person, and
Figure 2b illustrates an EMG-signal of a Parkinson patient.
The use of nonlinear methods in examinations of Parkinson's disease is based on the fact that the EMG-signal of Parkinson patients differs from the EMG of healthy persons. In figure 1 there is an example of so-called RAW EMG-signal during static contraction. An EMG-signal is a sum signal of individual action potentials caused by motor units in a muscle. Normal motoric control of a muscle causes always slight fading in an EMG-signal even visible in the figure as well as separate and oc-
casional spikes. Proportion of various deviations on a healthy person is quite small and no regularities may be found.
In figure 2a and 2b there are EMG measurements of three seconds duration on a healthy control person (figure 2a) and on a Parkinson patient (2b) presented. The measurements have been made during an isometric muscle contraction when the load of muscles remains as constant as possible on the average. Differences in re¬ cruiting of motor units on the healthy test person and on the Parkinson disease pa¬ tient are visible with the eye. In the signal of the healthy person, some individual spikes higher than the variation of the base level may be seen. In the signal of the Parkinson patient, however, clearly more signal spikes stronger than the base level may be seen and they repeat more regularly and more organized than on the healthy test person. Increasing of strong spikes is caused by interruptions in motoric control. As the result of this, the motor units of the muscle function more synchronized among each other, which means growing of the signal level in the EMG-signal. In practice, the excessive synchronization of motor units means tremor of muscles and absence of fine motoric control necessary for even motion.
The diagnosis method of Parkinson's disease is based on measuring made on a test person with an EMG-equipment and comparing of measuring results to comparison data in a database. Typically, an EMG-measurement is carried out on the muscles of the arm as the motoric control of arms is the most developed form of neuromuscular function. EMG-signal samples are taken with various standard motion course and power tests, in which case comparison of results with the database is possible. The motion courses to be tested are e.g. removing of an object of certain size and weight from one place to another along defined course. Along the course, the arm and the wrist must simultaneously e.g. clasp the object, move in horizontal and vertical di¬ rections as well as twist from one extreme position to another. In addition, the spon¬ taneous EMG-responses of the muscle may also be analyzed and separate the healthy and the Parkinson patients on grounds of the measuring data by a normal every day muscle activation analysis.
The comparison database contains sample data both from the healthy and from the patients in various phases of Parkinson's disease. In this case, the EMG-sample from a test person may give suggestions not only about the first symptoms of the disease but also about the proceeding degree of the disease. The results are normal¬ ized on grounds of data base comparison such that the proceeding degree may be categorized with a suitable scale.
The method may also be applied in dosing of medical treatment of Parkinson's dis¬ ease. The patient has an automatic dosing apparatus adjusted, which e.g. infuses medicine to the blood circulation or to the small intestine of the patient by means of estimation of the dopamine level based on EMG-measuring. EMG-measuring is made, for example, by means of a measuring wristband, which is easy to use and continuously functioning. A measuring wristband or other sensor is placed, for ex¬ ample, on the hand, feet and so on. Response from the measuring signal is analyzed at regular time intervals, for example every 5 min. When in the EMG-response, the analysis of which has been carried out by means of some nonlinear algorithms men- tioned, has visible signs of falling of the dopamine level, the information is trans¬ mitted to the device the patient is carrying. The device may be a dosing pump or some other dozer of medicine, which has e.g. an alarm system for starting the dos¬ ing or for a dose of medicine to be taken internally. In more advanced models, sy¬ ringing may start automatically through an invasive canule. It is also characteristic to Parkinson's disease that the symptoms appear first on one limb, in which case by comparing signals both on the left and the right limb the ending of the influence of medicine may be anticipated in good time.
Overdosing of medicine may also cause adaptation of a patient to dopamine as the result of which the influence of medicine dose weakens. At the worst adaptation may facilitate the progression of the disease or cause premature death. By means of the device in accordance with the invention, a possible medicine overdosing may be avoided.
In an advantageous application of the invention pain response experienced by pa¬ tients suffering from back pain in comparison with feelings of patients with similar by performance ability of muscles but with no pain. Condition of back muscles of patients with back problems has weakened and a part of patients suffers from pain also while loading muscles. Patients with back pain may be separated from healthy patients who have been through treatment/training by means of FFT method based on linear analysis, but the method does not separate individually pain patients. Identification of pain patients is successful while using the nonlinear RQA method and the method makes it possible to make a measurement from a measuring signal before rehabilitating exercise part and after it, whereas earlier the measurement had to be carried out with a linear method during the whole performance. In RQA method, reducing of % determinism has been proved to correlate with the decreas- ing feeling of pain of a patient.
In another advantageous application of the invention, the method is utilized in measuring of fatigue during dynamic motion. In the patent US 5,361,775 of Mega Elektroniikka Oy a FFT analysis made from so-called RAW EMG-signal is de¬ scribed, by means of which analysis quantities correlating with muscle fatigue are calculated. The method has been proved functionable while measuring muscle fa¬ tigue during static load. FFT calculation gives suggestive results also during dy¬ namic motion but muscle contractions varying continuously and interferences due to motion change the frequency content of the EMG-signal such that the results from FFT calculations are not as precise and reliable as in static measurement. FFT calculation made of dynamic motion may be specified by making use of motion sensors attached to a person during the test, by means of which sensors the interfer¬ ences created in signals may be eliminated or limit the areas included in FFT calcu¬ lation to advantageous in terms of calculation. In this case fatigue may be measured reliably e.g. during work or sports performance with a measuring/displaying device to be carried with a person.
An advantageous application of the invention measures development of motoric skills of a person. The method is utilized e.g. in rehabilitation after a person has been disabled, in training of professions requiring great accuracy or e.g. in sports training. EMG-signal is measured from one or several muscles during a perform- ance. During the measurement a specific performance and its training part are aimed to be specified e.g. a golf swing or a tennis serve. The measuring sensors are placed on the skin overlying muscles participating in the performance at the middle of the muscle. The measuring is carried out through disposable sensors or through sensors integrated in clothing. The information of measuring is stored in a measuring device on the wrist, on the waist or in the pocket, which measures the EMG-signal with recognized methods. The measuring signal is calculated by means of various calcu¬ lation algorithms, by calculating e.g. complexity values during the performance. The performance is tried to be separated into various phases and the result of the performance is fed also into the memory of the device. Complexity values from the entire performance are calculated and stored into the memory. As the motoric level develops the signal of complexity changes and the time-related synchronisation of muscles during a performance improves. The change is compared to the received performance results. Later on, the values may be utilized while restoring and further developing motoric skills. The results may be compared to the values of the data- base and in this way estimate the development of motoric learning and skill objec¬ tively.
In an advantageous application of the invention, the method is utilized for measur¬ ing the activeness level of a person which is necessary for follow-up of changes in activeness state of the central nervous system due to various reasons e.g. in connec¬ tion with diseases such as dementia, Alzheimer disease, depression, chronic/acute fatigue and so on. Control of the state of fatigueness is useful also in some working positions requiring continuous concentrating such as surgery, flying/air control and so on.
In this application, the median value of a person is defined for complexity, which is compared to reference data. The person to be measured carries a measuring device, which measures at regular time intervals e.g. EMG-signal from the muscles of the arms, from which signal some of the parameters complexity, entropy or determin¬ ism is calculated. From the value, e.g. the mean value of a day or a week is calcu¬ lated. The change with respect to the mean value on a long time period describes the change in activeness, variation in serotonin level, motoric learning and so on.
The device in accordance with the invention comprises sensors to be placed in the body or on the body surface for measuring signals produced by muscles, a device for analysis of the signals by nonlinear calculation methods and a feedback device for giving feedback. The device comprises advantageously sensors especially for measuring electrical signals produced by muscles. The sensors in themselves are conventional sensors for this purpose. The device for analysis of signals processes and analyzes signals and it has the necessary programmes for processing and ana¬ lyzing signals with nonlinear calculation methods as earlier presented. In addition, the device comprises one or several recognized feedback devices, with which the user, the person examined or possibly some other person may receive information about the study and its results in real-time or later. Naturally, the information is also stored for later use.
The invention is not limited to the presented advantageous applications but it can vary within the frames of the idea of the invention formed in the claims.
Claims
1. A method for identifying, measuring and analyzing abnormal neurological re¬ sponses, characterized in that neurological diseases, pain, fatigue, power producing ability and/or activeness and/or symptoms connected with those are esti- mated by measuring signals produced by muscles and by analyzing signals with nonlinear calculation methods.
2. A method in accordance with claim 1, characterized in that electrical sig¬ nals of muscles are measured with a measuring device.
3. A method in accordance with claim 1 or 2, characterized in that electrical signals of active muscles are measured with a measuring device.
4. A method in accordance with any of claims 1,2 or 3, characterized in that results received by the method are compared to reference results stored in a da¬ tabase.
5. A method in accordance with any of claims 1-4, characterized in that the results received by the method are transmitted to a user by means of a feedback de¬ vice.
6. A method in accordance with any of claims 1-4, characterized in that the received results are transmitted to the person examined by means of a personal feedback device.
7. A method in accordance with any of claims 1-6, characterized in that Parkinson's disease is diagnosized, the influence of rate of dosage of medicine is defined, monitored and controlled and the progression of the disease is followed by the method.
8. A method in accordance with any of claims 1-7, characterized in that pain is diagnosized, the influence of rate of dosage of medicine is defined, moni¬ tored and controlled and the influence of pain is followed by the method.
9. A method in accordance with any of claims 1-8, characterized in that the degree of fatigueness is measured by the method.
10. A method in accordance with any of claims 1-9, characterized in that power producing ability and changes in it are measured by the method.
1 LA method in accordance with any of claims 1-10, characterized in that activeness of the central nervous system and changes in it are measured by the method.
12.A device for identifying, measuring and analyzing abnormal neurological re- sponses, characterized in that the device comprises sensors to be placed in the body or on the body surface for measuring signals produced by muscles, a signal analyzing device for analyzing signals with nonlinear calculation algorithms and a feedback device for giving feedback.
13. A device in accordance with claim 12, characterized in that the device comprises sensors to be placed in the body or on the body surface for measuring electrical signals produced by muscles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58992804P | 2004-07-20 | 2004-07-20 | |
PCT/FI2005/000330 WO2006008334A1 (en) | 2004-07-20 | 2005-07-18 | Method and device for identifying, measuring and analyzing abnormal neurological responses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1838214A1 true EP1838214A1 (en) | 2007-10-03 |
EP1838214A4 EP1838214A4 (en) | 2009-04-15 |
Family
ID=35784897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05771542A Withdrawn EP1838214A4 (en) | 2004-07-20 | 2005-07-18 | Method and device for identifying, measuring and analyzing abnormal neurological responses |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1838214A4 (en) |
WO (1) | WO2006008334A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007312921A (en) * | 2006-05-24 | 2007-12-06 | Casio Comput Co Ltd | Biological information measuring apparatus and biological information measuring system |
WO2008122082A1 (en) * | 2007-04-04 | 2008-10-16 | Brc Ip Pty Ltd | Brain function parameter measurement system and method |
US8386025B2 (en) | 2007-04-30 | 2013-02-26 | IctalCare A/S, Delta | Device and method for monitoring muscular activity |
BR112013008896A2 (en) | 2010-10-15 | 2016-06-28 | Lgch Inc | "method and apparatus for detecting seizures" |
US10226209B2 (en) | 2010-10-15 | 2019-03-12 | Brain Sentinel, Inc. | Method and apparatus for classification of seizure type and severity using electromyography |
CA2840101A1 (en) | 2011-07-05 | 2013-01-10 | Lgch, Inc. | Method and apparatus for detecting seizures |
US20190083027A1 (en) * | 2016-03-29 | 2019-03-21 | The Governors Of The University Of Alberta | Spinal assessment system |
MX2018012853A (en) | 2016-04-19 | 2019-03-28 | Brain Sentinel Inc | Systems and methods for characterization of seizures. |
FI128143B (en) * | 2017-06-15 | 2019-10-31 | Bittium Biosignals Oy | Method and portable monitoring module for monitoring a plurality of electrical biosignals of a person |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0405465A2 (en) * | 1989-06-27 | 1991-01-02 | Empi, Inc. | Method for treating electromyographic signals |
US20020173729A1 (en) * | 2001-05-18 | 2002-11-21 | Hanna Viertio-Oja | Closed loop drug administration method and apparatus using eeg complexity for control purposes |
WO2003086188A2 (en) * | 2002-04-15 | 2003-10-23 | Instrumentarium Corporation | Method and apparatus for determining the cerebral state of a patient with fast response |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5092343A (en) * | 1988-02-17 | 1992-03-03 | Wayne State University | Waveform analysis apparatus and method using neural network techniques |
US5361775A (en) * | 1993-04-06 | 1994-11-08 | Mega Elektroniikka Oy Pl. | Method for determining muscle endurance and sensitivity to fatigue |
US5662118A (en) * | 1995-06-01 | 1997-09-02 | Skubick; Daniel Lewis | System for diagnosing musculoskeletal disorders |
US6643541B2 (en) * | 2001-12-07 | 2003-11-04 | Motorola, Inc | Wireless electromyography sensor and system |
ITFI20030024A1 (en) * | 2003-01-31 | 2004-08-01 | Enel Produzione Spa | ELECTROMYOGRAPHIC SIGNALS PROCESSING SYSTEM AND METHOD |
-
2005
- 2005-07-18 EP EP05771542A patent/EP1838214A4/en not_active Withdrawn
- 2005-07-18 WO PCT/FI2005/000330 patent/WO2006008334A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0405465A2 (en) * | 1989-06-27 | 1991-01-02 | Empi, Inc. | Method for treating electromyographic signals |
US20020173729A1 (en) * | 2001-05-18 | 2002-11-21 | Hanna Viertio-Oja | Closed loop drug administration method and apparatus using eeg complexity for control purposes |
WO2003086188A2 (en) * | 2002-04-15 | 2003-10-23 | Instrumentarium Corporation | Method and apparatus for determining the cerebral state of a patient with fast response |
Non-Patent Citations (2)
Title |
---|
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2004 (2004-05), LIU YIWEI ET AL: "EMG recurrence quantifications in dynamic exercise." XP002517319 Database accession no. NLM15221394 & BIOLOGICAL CYBERNETICS MAY 2004, vol. 90, no. 5, May 2004 (2004-05), pages 337-348, ISSN: 0340-1200 * |
See also references of WO2006008334A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006008334A1 (en) | 2006-01-26 |
EP1838214A4 (en) | 2009-04-15 |
WO2006008334A8 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Celik et al. | Gait analysis in neurological populations: Progression in the use of wearables | |
Steptoe et al. | Individual differences in the perception of bodily sensations: The role of trait anxiety and coping style | |
WO2006008334A1 (en) | Method and device for identifying, measuring and analyzing abnormal neurological responses | |
Chen et al. | Design of an integrated wearable multi-sensor platform based on flexible materials for neonatal monitoring | |
Iqbal et al. | A sensitivity analysis of biophysiological responses of stress for wearable sensors in connected health | |
US20070066874A1 (en) | Methods and devices for analyzing and comparing physiological parameter measurements | |
CN106999065A (en) | Use the wearable pain monitor of accelerometry | |
Malathi et al. | Electrodermal activity based wearable device for drowsy drivers | |
US20070118044A1 (en) | Method and device for identifying; measuring and analyzing abnormal neurological responses | |
Cecchi et al. | Physical stimuli and emotions: EDA features analysis from a wrist-worn measurement sensor | |
JP2020161187A (en) | Method, device, and program for evaluating relevance between health degree of interest health region and each preventive intervention action | |
Ramírez et al. | Assessment of emotional states through physiological signals and its application in music therapy for disabled people | |
EP4037565A1 (en) | Systems and methods for monitoring the state of a disease using a biomarker, systems and methods for identifying a biomarker of interest for a disease | |
Ismail et al. | Hand motion pattern recognition analysis of forearm muscle using MMG signals | |
Sheng et al. | Metric-based muscle synergy consistency for upper limb motor functions | |
Yu et al. | Wireless medical sensor measurements of fatigue in patients with multiple sclerosis | |
Altini et al. | Personalizing energy expenditure estimation using a cardiorespiratory fitness predicate | |
Chu et al. | Physiological signals based quantitative evaluation method of the pain | |
Yiu et al. | Fatigue-Related change in surface electromyographic activities of the perilaryngeal muscles | |
WO2024108662A1 (en) | Apparatus and method for monitoring muscle fatigue in real time | |
TW202410067A (en) | Method for disease risk assessment | |
Tokmak et al. | Unveiling the relationships between seismocardiogram signals, physical activity types and metabolic equivalent of task scores | |
Gogate et al. | Hunger and stress monitoring system using galvanic skin | |
Gentry et al. | Activity segmentation using wearable sensors for DVT/PE risk detection | |
RU2257143C1 (en) | Method for evaluating efficiency in restoring vertical posture in patients with statodynamic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070207 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090312 |
|
17Q | First examination report despatched |
Effective date: 20090724 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100204 |